luteinizing hormone

Luteinizing hormone (LH), a heterodimeric glycoprotein hormone synthesized by the pituitary gland, serves vital functions in human reproductive processes.

Luteinizing Hormone Releasing Hormone (LH-RH), synthesized in the hypothalamus, is a pituitary hormone that plays a crucial role in controlling reproductive function.

Recombinant Human Luteinizing Hormone is the reconstituted version of Luteinizing hormone (human). This heterodimeric glycoprotein hormone, produced by the pituitary gland (LH), plays a crucial role in human reproduction.

Gonadorelin Acetate (33515-09-2 free base) (Luteinizing Hormone Releasing Hormone (LH-RH)) is hypothalamic neuropeptide which plays a key role in the control of reproductive functions.

LH-RH, salmon acetate(86073-88-3 free base) (Luteinizing Hormone Releasing Hormone (LH-RH), salmon acetate) is a pituitary Hormone synthesized in the hypothalamus and plays a crucial role in the control of reproductive function.

Seganserin, a non-selective 5-hydroxytryptamine 2-HT receptor antagonist, reversed the inhibitory effects of fluoxetine and quipazine on luteinizing hormone-induced hyperphagia, depression and nociception, and reversed the antidepressant and analgesic effects induced by fluoxetine and quipazine.

Cyproterone acetate (Cyproterone 17-O-acetate) binds the androgen receptor (AR), thereby preventing androgen-induced receptor activation in target tissues and inhibiting the growth of testosterone-sensitive tumor cells. Cyproterone acetate is the acetate salt of a synthetic steroidal antiandrogen with weak progestational and antineoplastic activities. This agent also exerts progestational agonist properties at the level of the pituitary that reduce luteinizing hormone (LH), resulting in reductions in testicular androgen secretion and serum testosterone levels. Treatment with cyproterone alone results in incomplete suppression of serum testosterone levels.Cyproterone binds the androgen receptor (AR), thereby preventing androgen-induced receptor activation in target tissues and inhibiting the growth of testosterone-sensitive tumor cells. Cyproterone Acetate is the acetate salt of a synthetic steroidal antiandrogen with weak progestational and antineoplastic activities. This agent also exerts progestational agonist properties at the level of the pituitary that reduce luteinizing hormone (LH), resulting in reductions in testicular androgen secretion and serum testosterone levels. Treatment with cyproterone alone results in incomplete suppression of serum testosterone levels.

Relugolix (RVT-601) is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.

16a,17a-Epoxy-4-Pregnen-3,20-Dione is a synthetic progestin, a metabolite of the luteinizing hormone hormone, which acts by binding to the luteinizing hormone receptor. It has been used to study the effects of progesterone on reproductive organs, the effects of the hormone on cell growth and development, and the effects of the hormone on the immune system.

BAY 1214784 is a selective and orally active human GnRH-R (Human Gonadotropin-Releasing Hormone Receptor) antagonist, which can effectively reduce plasma luteinizing hormone levels by up to 49% and can be used for the study of uterine fibroids.

LH secretion antagonist 1 is a luteinizing hormone secretion antagonist with analgesic activity.

BAY-298 is an orally active and selective luteinizing hormone receptor (LH-R) antagonist with IC50s of 96 nM, 23 nM, and 78 nM for hLH (human LH), rLH (rat LH), and cLH (cynomolgus monkey LH), respectively. It is the first nanomolar hLH-R antagonist that reduces sex hormone levels in vivo [1].

BAY-899 is an orally active and selective antagonist of the luteinizing hormone receptor (LH-R), with IC50 values of 185 nM for human LH (hLH) and 46 nM for rat LH (rLH). In vivo studies have shown that BAY-899 effectively reduces sex hormone levels[1].

Zuclomiphene citrate, a cis isomer of Clomiphene citrate, exhibits an antiestrogenic effect and inhibits the secretion of luteinizing hormone (LH) more effectively than its trans isomer.

Pentacosafluorotridecanoic Acid (PFTrDA) is a perfluoroalkyl substance (PFAS) that exhibits various biological impacts across different species. In zebrafish embryos, exposure to PFTrDA induces yolk sac edema and increases mRNA expression of thyroid hormone synthesis genes, including tshβ, at concentrations of 0.1 and 0.3 mg/L. At a dosage of 10 mg/kg, PFTrDA reduces serum testosterone and luteinizing hormone levels, as well as palmitic acid, linoleic acid, and oleic acid levels in the testicular interstitial cells of late adolescent rats. In humans, maternal plasma levels of PFTrDA during pregnancy are positively correlated with the development of eczema in female infants (but not male infants), and PFTrDA levels are higher in the livers of cancerous humans compared to non-cancerous ones. Additionally, PFTrDA is found in marine mammals.

ADX61623 is an effective negative allosteric modulator (NAM) of the follicle-stimulating hormone receptor (FSHR). It also exhibits activity on the luteinizing hormone receptor (LH-R) but is inactive on the thyroid-stimulating hormone (TSH) receptor. ADX61623 can be utilized in research on estrogen-dependent diseases.

Nafarelin is a gonadotropin-releasing hormone (GnRH) agonist. Nafarelin increases the release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) by the anterior pituitary leading to an increase of estrogen/progesterone.

NK3R-IN-2 is an orally active NK3R inhibitor with an IC50 of 330.50 nM against human NK3R. It can penetrate the blood-brain barrier and exhibits excellent NK3R binding affinity in CHO-K1 cells (IC50= 87.31 nM). NK3R-IN-2 effectively suppresses luteinizing hormone (LH) levels and is applicable for research on hormone-related diseases.

Nafarelin acetate(76932-56-4 free base) (RS-94991-298) is a GnRH agonist that acts as an analog of GnRH. Nafarelin acetate(76932-56-4 free base) causes a decrease in the pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH). It may be used in the treatment of estrogen-dependent conditions.

Clomifene is a selective estrogen receptor modulator (SERM), it has both estrogenic and anti-estrogenic activities. This agent causes the release of the pituitary gonadotropins follicle-stimulating hormone (FSH) and luteinizing hormone (LH), leading to ov

Triptorelin acetate(57773-63-4 free base) (CL 118,532) is used as a GnRH agonist. It decreases pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH) by causing constant stimulation of the pituitary. Triptorelin acetate(57773-63-4 free base) may be used in the treatment of hormone-responsive cancers such as breast cancer or prostate cancer, precocious puberty, estrogen-dependent conditions, and assisted reproduction.

Bornaprolol (FM-24) is a β-adrenoceptor antagonist that significantly reduces plasma levels of luteinizing hormone (LH) in castrated rat models. It is applicable in research related to cardiovascular diseases such as hypertension and angina.

Propiomazine maleate is an orally active antihistamine. It acts as a potent stimulant for prolactin (PRL) release through antagonism of the dopaminergic system and inhibits luteinizing hormone (LH) secretion. Propiomazine maleate is primarily utilized as an adjunct in anesthesia, in the management of psychiatric disorders and anxiety sedation, and is also used in research related to insomnia.

2-Hydroxysaclofen is a potent γ-amino-butyric-acid-B receptor antagonist that effectively abolishes nicotine-induced hypolocomotor effects, enhances antinociceptive responses, and stimulates luteinizing hormone secretion in female rats, making it a valuable pharmacological probe for investigating GABAB receptor–mediated neuroendocrine regulation and behavioral pharmacology.